SynthesisInternational urology and nephrology2026
Renal medullary carcinoma: a systematic review of clinical and radiological findings.
Synthesis in International urology and nephrology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BACKGROUND AND
aimsRenal medullary carcinoma (RMC) is a rare subtype of renal cell carcinoma, typically described in young patients with sickle cell trait, which follows an aggressive course. We aimed to perform a systematic review of all published cases of RMC from 1995 to 2024, to summarise the clinico-pathological and radiological features.
methodsA systematic review of all published cases of RMC from 1995 to 2024 was performed. Patient demographics, clinical presentation, radiological features, metastatic profile, management, and overall survival were recorded. Sub-analysis was performed, grouped by sickle cell status.
results219 cases from 103 articles were included, in addition to 5 previously unreported cases from our institution. 88% of patients had sickle cell haemoglobinopathy (SCH) (n = 168/192), with presentation at a younger age in patients with SCH (27.3 ± 13.7 versus 34.1 ± 19.1 years, p = 0.001). RMC was more frequently observed in the right kidney (64.6%, n = 122/189) than the left kidney (35.4%, n = 67/189) (p = < 0.001). Radiologically, the most common features were a central/endophytic location, hypo-enhancement relative to the adjacent cortex, and infiltrative margins. 20.7% (n = 42/203) were stage III at presentation and 70.9% (n = 144/203) of patients were Stage IV. Overall survival at 3 years was 74% for Stage I-II disease, 23% for Stage III disease, and 9% for Stage IV disease.
conclusionsRegardless of sickle cell status, RMC was shown to present at a relatively young age. It was classically seen as an infiltrative, poorly defined, endophytic tumour, centred on the renal medulla. RMC was found to be more commonly advanced at presentation and the overall survival in patients with nodal or distant metastases was poor.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.